---
layout: default
title: Anemone Patens Whole Apis Mellifera Carbon Disulfi
parent: 僅模型預測 (L5)
nav_order: 322
evidence_level: L5
indication_count: 0
---

# Anemone Patens Whole Apis Mellifera Carbon Disulfi
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ANEMONE PATENS / APIS MELLIFERA / SEPIA Combination: Evaluation Incomplete — Insufficient Data for Repurposing Analysis

## One-Sentence Summary

This drug entry is a multi-component homeopathic combination product (Anemone Patens Whole, Apis Mellifera, Carbon Disulfide, Sepia Officinalis Juice, Silicon Dioxide) with no registered market authorization in the United States.
The TxGNN model was **unable to generate any repurposing predictions** for this compound, as no DrugBank ID could be resolved and no original indication is on record.
This evaluation cannot proceed beyond the data intake stage without substantial remediation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not on record |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction unavailable; no supporting studies |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This compound is a **homeopathic combination product** comprising five ingredients that are not individually catalogued in the DrugBank knowledge graph:

| Ingredient | Class |
|-----------|-------|
| Anemone Patens Whole (Pulsatilla) | Homeopathic botanical |
| Apis Mellifera | Homeopathic animal-derived |
| Carbon Disulfide | Homeopathic mineral |
| Sepia Officinalis Juice | Homeopathic animal-derived |
| Silicon Dioxide | Homeopathic mineral |

Because TxGNN operates on the DrugBank–disease knowledge graph, it requires a resolvable DrugBank ID to generate a score. Since no component of this mixture could be mapped, the prediction pipeline returned zero candidates. This is not a signal of inefficacy — it is a signal of **data incompatibility** between the drug's representation and the model's input requirements.

---

## Safety Considerations

Please refer to the product's package insert for safety information. No drug–drug interaction records, key warnings, or contraindications were retrieved from available databases for this compound.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN could not produce any repurposing predictions because this homeopathic combination lacks a DrugBank ID and has no original approved indication on record. Without a knowledge-graph anchor, the entire downstream evaluation pipeline (predictions → evidence → safety scoring) cannot execute.

**To proceed, the following is needed:**

- **Resolve component identities**: Determine whether any of the five ingredients (especially Apis Mellifera venom or Pulsatilla alkaloids) have individual DrugBank or ChEMBL entries that can be submitted separately to TxGNN.
- **Clarify product intent**: Confirm whether the intended analysis target is the whole combination product or one specific active ingredient (e.g., apamin from Apis Mellifera).
- **Obtain TFDA/FDA package insert**: If a prior authorization existed in any jurisdiction, retrieve the official product monograph to establish original indication and MOA baseline.
- **Consider ingredient-level re-analysis**: Submit each individual INN (e.g., "apamin", "pulsatilla total alkaloids") as a separate Evidence Pack query to check for TxGNN coverage.
- **Assess whether homeopathic products are in scope**: Determine whether this product category is intended to be included in the repurposing pipeline or should be flagged as out-of-scope.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

